Phase 4 N=21 Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients
Hepatitis C · HIV Infections
Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants
Phase 2 N=67 Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
HIV Infection · Hepatitis C Infection
Primary: Percentage of Participants With Complete Early Virologic Response (cEVR) — 38.8 percentage of participants
Phase 2 N=36 Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
Hepatitis C · HIV Infections
Primary: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response — 8 participants with post treatment svr
Phase 4 N=18 HCV-HIV Co-infected Patient Cohort in Thailand
Hepatitis C Infection · HIV
Primary: Number of Participants With Sustained Virological Response 6 Months After Treatment Discontinuation — 10 Participants
Phase 2 N=255 Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)
HIV Infections · Hepatitis C · Liver Disease
Primary: Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS) — 0; 0 Metavir units per one year (52 weeks) — p=0.58
N/A N=68 Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection
HIV · Hepatitis C, Chronic
Primary: Number of Participants Linked to Care — 8; 16 Participants — p=0.036
Phase 2 N=62 Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
Hepatitis C · HIV Infections
Primary: Proportion of Subjects Achieving Undetectable HCV RNA at Week 12 — 6; 2; 14; 2 participants
Phase 3 N=262 Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
HIV Infections · Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) — 34.8; 25.4 percentage of participants
Phase 2 N=30 Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
HIV-HCV
Primary: The Percentage of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 90; 80 Percentage of subjects
Phase 3 N=203 A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
Hepatitis C
Primary: Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Treatment-naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) — 96.4 Percentage…
Phase 3 N=107 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 95.3 percentage of participants
Phase 4 N=137 A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
HIV Coinfection
Primary: Percentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 48 — 1.4; 1.5 Percentage of participants — p=0.4598
Phase 2 N=50 Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV
Hepatitis C · HIV
Primary: Percentage of Participants With Achieved SVR12 (HCV RNA <LLOQ 12 Weeks After Completion of Treatment) — 97; 100 percentage of participants
Phase 4 N=180 Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response (SVR) — 23.8; 36.5 percentage of participants — p=0.0536
Phase 4 N=600 Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia
HCV HIV
Primary: Number of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 516 Participants
Phase 4 N=415 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection
Hepatitis C, Chronic
Primary: Sustained Virological Response (SVR) — 19; 22 Percentage of participants — p=0.6119
Phase 3 N=301 Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
Hepatitis C, Genotype 1
Primary: Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) — 75; 71.8; 71.7; 73.3 Percentage of participants
Phase 3 N=275 A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Chronic Hepatitis C · Human Immunodeficiency Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 89.5; 84.8; 84.0; 90.9 percentage of participants
Phase 2 N=19 Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
HIV-1 and Hepatitis C Co-Infection
Primary: The Proportion of All Subjects With HCV Viral Load < 60 IU/mL at Week 24 of Step 2. — 0.158 proportion of participants — p=0.29
N/A N=348 Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
Hepatitis C, Chronic
Primary: Number of Participants Who Completed Treatment With PegIFN-2b/Ribavirin — 56; 150 participants
Phase 4 N=68 Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
HIV · Hepatitis C · Cirrhosis
Primary: Number of Participants With Sustained Virologic Response (SVR) — 38; 25 Participants
Phase 3 N=318 A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
Hepatitis C Virus Infection · Human Immunodeficiency Virus Infection · Chronic Hepatitis C
Primary: Percentage of Participants in GT1 Analysis Group 1 in Part 2 Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) — 97.0 percentage of participants
Phase 3 N=106 A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1
Hepatitis C Virus Genotype-1
Primary: Percentage of Participants With Sustained Virologic Response at Week 12 (SVR 12) — 73.6 percentage of participants
Phase 3 N=335 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
Hepatitis C Virus · HIV
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 96.1 percentage of participants
Phase 2 N=45 Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
Hepatitis C Infection · HIV Infection
Primary: Percentage of Participants With Sustained Virologic Response at 12 Weeks Post Treatment Discontinuation (SVR12) — 84.4 percentage of participants
Phase 1 N=44 Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
HIV-1 Infection · Hepatitis
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 58.8; 100.0 Percentage of participants
N/A N=198 Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
HCV · Buprenorphine · PreP
Primary: Hepatitis C Virus (HCV) Cure (Sustained Virologic Response) — 158 Participants
Phase 4 N=80 Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
Hepatitis C, Chronic · HIV Infection
Primary: Rates of Grade 2 and Higher Alanine Aminotransferase (ALT) Elevations — 24; 30 Participants
Phase 2 N=146 Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C
Hepatitis C
Primary: A Comparison of the Percentage of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of Treatment. — 28.8; 31.5…